Cardioprotection by Sevoflurane Preconditioning in Noncardiac Thoracic Surgery
Not Applicable
Completed
- Conditions
- High Sensitive Troponin T Release
- Interventions
- Drug: TIVA
- Registration Number
- NCT02217319
- Lead Sponsor
- Dr. Horst Schmidt Klinik GmbH
- Brief Summary
It has been shown that the use of volatile anaesthetics, that are usually used to perform a general anesthesia, have cardioprotective properties. This has been shown in animal studies and in patients that underwent cardiac surgery. The aim of our study is to examine if Sevoflurane, a volatile anaesthetic, has this properties in patients undergoing lung surgery.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Lung surgery
- ASA (American Society of Anesthesiologists) physical status 1-3
Exclusion Criteria
- Disposition for malignant hyperthermia
- Medication with ß-blocking drugs
- Use of clonidin
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Sevoflurane Sevoflurane Patients receive Sevoflurane 1 MAC (minimal alveolar concentration) after induction of anesthesia with propofol, remifentanil and atracurium for 30 minutes as preconditioning. TIVA TIVA Patients received the standard total intravenous anesthesia (TIVA) with propofol, remifentanil and atracurium.
- Primary Outcome Measures
Name Time Method Troponin T change of Troponin T levels preoperative and postoperative up to 40 hours after surgery assessing a change in high sensitive Troponin T (5th generation) Level before and at six time points after surgery (right after surgery, every 8 hours up to 40 hours after surgery)
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Dr Horst Schmidt Klinik
🇩🇪Wiesbaden, Germany